Illumina, Inc. (ILMN) Shares Sold by NEXT Financial Group Inc

NEXT Financial Group Inc trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 13.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,319 shares of the life sciences company’s stock after selling 498 shares during the period. NEXT Financial Group Inc’s holdings in Illumina were worth $687,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Illumina by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after purchasing an additional 255,498 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in Illumina by 3.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock worth $500,416,000 after purchasing an additional 76,452 shares in the last quarter. Capital World Investors increased its holdings in Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares in the last quarter. TIAA CREF Investment Management LLC increased its holdings in Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares in the last quarter. Finally, Winslow Capital Management LLC bought a new stake in Illumina during the 2nd quarter worth approximately $211,584,000. 90.76% of the stock is owned by institutional investors and hedge funds.

WARNING: This story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/20/illumina-inc-ilmn-shares-sold-by-next-financial-group-inc.html.

ILMN has been the subject of a number of recent research reports. Leerink Swann reissued an “outperform” rating and set a $225.00 price objective (up from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Piper Jaffray Companies reissued an “overweight” rating and set a $226.00 price objective (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Citigroup Inc. boosted their price objective on Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a report on Wednesday, October 25th. Janney Montgomery Scott raised Illumina from a “sell” rating to a “neutral” rating in a report on Monday, October 23rd. Finally, Bank of America Corporation boosted their price objective on Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company’s stock. Illumina presently has a consensus rating of “Hold” and an average target price of $200.88.

Illumina, Inc. (NASDAQ:ILMN) traded up $0.51 during trading hours on Monday, hitting $209.02. The company’s stock had a trading volume of 545,500 shares, compared to its average volume of 959,780. The stock has a market capitalization of $30,516.92, a P/E ratio of 61.12, a P/E/G ratio of 3.45 and a beta of 0.74. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.50. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.97 earnings per share. equities analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current year.

In other news, EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $205.48, for a total value of $410,960.00. Following the transaction, the executive vice president now owns 30,370 shares of the company’s stock, valued at $6,240,427.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $205.71, for a total transaction of $29,827.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 172,446 shares of company stock worth $35,486,114. Company insiders own 0.89% of the company’s stock.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply